Results 61 to 70 of about 4,368 (201)
Enantioselective Total Synthesis of (‐)‐Finerenone using Asymmetric Transfer Hydrogenation [PDF]
, 2020 (‐)‐Finerenone is a nonsteroidal mineralocorticoid receptor antagonist currently in phase III clinical trials for the treatment of chronic kidney disease in type 2 diabetes. It contains an unusual dihydronaphthyridine core.
Farrar, Elliot +14 more
core +1 more source
Renal FailureAims Finerenone has been approved for treating diabetic kidney disease (DKD) with reducing cardiorenal risk. Real-world data on finerenone treatment for the management of DKD are presently lacking. This study aimed to investigate the effect of finerenone
Jingying Zhou +5 more
doaj +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8757-8768, October 2026.ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris +5 more
wiley +1 more source
ESC Heart FailureAims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce.
Gonzalo Luis Alonso Salinas +32 more
doaj +1 more source
Finerenone: features of action, current evidence base and examples of clinical application
Сахарный диабетThe article is devoted to the pharmacological and impairment features of finerenone, a new non-steroidal antagonist of mineralocorticoid receptors (AMR), like other drugs, suppresses the activity of the renin-angiotensin-aldosterone system (RAAS), which ...
A. D. Erlikh +5 more
doaj +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9054-9068, October 2026.ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan +7 more
wiley +1 more source
Baseline characteristics of patients with type 2 diabetes and chronic kidney disease, stratified by Finerenone ...
Chang, Kuang-Hsi
core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9403-9411, October 2026.ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii +5 more
wiley +1 more source
BMJ OpenObjectives This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex.Design FIDELITY post hoc analysis; median follow-up ...
George L Bakris +12 more
doaj +1 more source
Finerenone in the management of diabetes kidney disease [PDF]
BMC NephrologyPeople with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease.
De, Parijat +17 more
openaire +5 more sources